AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca has launched a new clinical study titled ‘A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours.’ The study aims to assess the safety, tolerability, and preliminary efficacy of AZD4360, an antibody-drug conjugate targeting Claudin 18.2, in adults with advanced solid tumors.
The intervention being tested is AZD4360, a drug designed as an antibody-drug conjugate to target Claudin 18.2, which is expressed in certain solid tumors. The purpose of this intervention is to evaluate its potential as a treatment option for these conditions.
The study follows an interventional design with a sequential intervention model and no masking, focusing primarily on treatment. This design allows for a clear assessment of the drug’s effects on the targeted tumors.
The study began on April 29, 2025, with the last update submitted on July 1, 2025. These dates are crucial as they mark the study’s progress and the timeline for potential results that could impact future treatment options.
From a market perspective, this study could influence AstraZeneca’s stock performance positively if the results show promising efficacy and safety, enhancing investor confidence. The competitive landscape in oncology treatments means that successful outcomes could position AstraZeneca favorably against competitors.
The study is currently ongoing, with further details available on the ClinicalTrials portal.